Patents by Inventor Margaret Shipp

Margaret Shipp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS
    Publication number: 20160279141
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20160215052
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: July 23, 2014
    Publication date: July 28, 2016
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
    Publication number: 20160187340
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 30, 2016
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • ANTI-GALECTIN-1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20160168236
    Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 16, 2016
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, kits, and methods for the modulation of immune responses using galectin-1
    Patent number: 9206427
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 8, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., CONICET, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
    Publication number: 20150191536
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 9, 2015
    Applicants: The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 8968740
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 3, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Compositions and Methods for the Modulation of DNA Damage Responses Using BAL1 and BBAP
    Publication number: 20150020221
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 15, 2015
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • Compositions, Kits, and Methods for the Identification, Assessment, Prevention, and Therapy of Cancer
    Publication number: 20150004158
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
    Publication number: 20130011409
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 10, 2013
    Applicants: Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Dana-Farber-Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Lymphoma associated molecules and uses therefor
    Patent number: 7858742
    Abstract: The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: December 28, 2010
    Assignee: Dana-Farber Cancer Institute
    Inventors: Margaret Shipp, Ricardo Aguiar, Yoshi Yakushijin
  • Lymphoma associated molecules and uses therefor
    Patent number: 7632660
    Abstract: The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: December 15, 2009
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Ricardo Aguiar, Liqun Gu, Kunihiko Takeyama
  • Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
    Publication number: 20090191182
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 30, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Quyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Immune Disorders Using Galectin-1
    Publication number: 20090176223
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 9, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich
  • Lymphoma associated molecules and uses therefor
    Publication number: 20070259342
    Abstract: The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Application
    Filed: May 9, 2005
    Publication date: November 8, 2007
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret Shipp, Ricardo Aguiar, Liqun Gu, Kunihiko Takeyama
  • Lymphoma associated molecules and uses therefor
    Patent number: 7112420
    Abstract: The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: September 26, 2006
    Assignee: Dana-Farber Cancer Institute
    Inventors: Margaret A. Shipp, Ricardo Aguiar, Liqun Gu, Kunihiko Takeyama
  • Nucleic acid sequence encoding lymphoma associated molecule BAL
    Patent number: 6870040
    Abstract: The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: March 22, 2005
    Assignee: Dana-Farber Cancer Institute
    Inventors: Margaret Shipp, Ricardo Aguiar, Yoshi Yakushijin
  • Lymphoma associated molecules and uses therefor
    Publication number: 20050014186
    Abstract: The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Application
    Filed: August 16, 2004
    Publication date: January 20, 2005
    Applicant: Dana-Farber Cancer Institute
    Inventors: Margaret Shipp, Ricardo Aguiar, Yoshi Yakushijin
  • Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
    Publication number: 20030194701
    Abstract: Methods for predicting phenotypic classes of lymphomas, such as lymphoma type or treatment outcome, for lymphoma samples based on gene expression profiles are described.
    Type: Application
    Filed: November 20, 2001
    Publication date: October 16, 2003
    Inventors: Todd R. Golub, Pablo Tamayo, Margaret Shipp, Eric S. Lander, Jon C. Aster
  • Lymphoma associated molecules and uses therefor
    Publication number: 20020120112
    Abstract: The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BBAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a BBAP gene has been introduced or disrupted. The invention still further provides isolated BBAP proteins, fusion proteins, antigenic peptides and anti-BBAP antibodies. Diagnostic methods using compositions of the invention are also provided.
    Type: Application
    Filed: September 19, 2001
    Publication date: August 29, 2002
    Applicant: Dana-Farber Cancer Institute
    Inventors: Margaret A. Shipp, Ricardo Aguiar, Liqun Gu, Kunihiko Takeyama